The demand for access to less invasive biopsy methods for cancer presents a critical decision for many provider laboratories. Access to in-house testing solutions has become an urgent need for many labs in order to provide rapid and accurate precision oncology services to oncologists that may improve treatment selection and outcomes for individuals, and enable laboratories to be more competitive in a fast-growing diagnostic market.

In this webinar, Dr. Melissa McConechy, Senior manager, Assay development at Canexia Health outlined the best practices and processes for transitioning to in-house testing including critical factors such as staffing, pre-analytical considerations for blood collection, sample input, limitations and generation of clinical reports.

 

Some key takeaways from the webinar include:

 

  • Key challenges that labs face to offer NGS-based panels for somatic mutations fall under three categories: 
    • Complex testing which include deep expertise in very diverse areas (such as oncology, genomics, computational biology, bioinformatics)
    • High level of quality assurance
    • Time and cost concerns 
  • Variability of input per sample directly affects input HGEs and thus the sensitivity for detecting ctDNA mutations
  • Setting up a liquid biopsy assay in your laboratory is achievable with the choice of  right assay and workflow
  • Canexia Health’s liquid biopsy assay demonstrated actionable results for patients as part of Access to Testing and Treatment (ACTT) project in Canada. 

Back

Recent Resources